Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug composition for synergistically resisting pancreatic cancer

An anti-pancreatic cancer and composition technology, which is applied in the field of combined drugs, can solve the problems such as the inability of chemotherapy drugs to cure pancreatic cancer and limit the application effect of gemcitabine, and achieve the effects of improving the safety index of clinical treatment, reducing the clinical dose and reducing toxic and side effects.

Active Publication Date: 2017-10-20
GUANGDONG UNIV OF TECH
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in clinical treatment, many pancreatic cancer patients have congenital or acquired chemotherapy resistance to gemcitabine, which limits the clinical application of gemcitabine
Therefore, the resistance of patients to chemotherapy drugs is also an important reason why pancreatic cancer is difficult to cure.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug composition for synergistically resisting pancreatic cancer
  • Drug composition for synergistically resisting pancreatic cancer
  • Drug composition for synergistically resisting pancreatic cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] A pharmaceutical composition for synergistic anti-pancreatic cancer, containing 1200 parts of triterpene compound E12 isolated from bougainvillea ethanol extract, 1 part of gemcitabine, and 600 parts of microcrystalline cellulose in molar quantities. Pack 100 capsules No. 1.

Embodiment 2

[0038] A pharmaceutical composition for synergistic anti-pancreatic cancer, containing 11,000 parts of triterpene compound E12-11000 parts isolated from bougainvillea alcohol extract, 10 parts of gemcitabine, and 300 parts of microcrystalline cellulose in molar quantities. Pack 100 capsules No. 1.

Embodiment 3

[0040] A pharmaceutical composition for synergistic anti-pancreatic cancer, containing 1600 parts of triterpene compound E13 isolated from bougainvillea ethanol extract, 1 part of gemcitabine, and 650 parts of lactose in molar quantities. After mixing evenly, add 300 parts of starch to prepare A 10% starch slurry was prepared for spray granulation. Then add 100 parts of magnesium stearate and 130 parts of PVP, after mixing evenly, tableting is made into 500 pieces.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a drug composition for synergistically resisting a pancreatic cancer. The drug includes an active component and a pharmaceutically acceptable auxiliary material and is characterized in that the active component includes gemcitabine and a triterpenoid; and the triterpenoid is 3 alpha, 11 alpha-dihydroxy-lupin-20(29)-ene-28-acid or 3 alpha-hydroxy-lupin-20(29)-ene-23, 28-diacid. According to the drug composition, the synergistic effect of combined medication to pancreatic cancer cells is judged on various aspects of a pancreatic cancer cell growth state, a cell growth inhibition percentage, influences of cell cycle and apoptosis and the like; and due to the drug resistance of the gemcitabine, by adopting combined medication, more medication safety is provided, clinic use dosage of the gemcitabine is lowered, the toxic and side effects generated by using a large dosage of the gemcitabine are reduced, the clinic treatment safety index is improved, and more possibilities are provided for clinic application of the gemcitabine.

Description

technical field [0001] The invention belongs to the technical field of combined medicines, and more specifically relates to a pharmaceutical composition for synergistically resisting prostate cancer. Background technique [0002] Pancreatic cancer is a common malignant tumor of the digestive tract with a high fatality rate. About 220,000 people die from this disease every year in the world, and its morbidity and mortality have increased significantly in recent years. In my country, the annual incidence of pancreatic cancer is about 5.1 cases per 100,000 people, and there are about 50,000 to 60,000 new cases every year. Its mortality rate also increases rapidly, accounting for the 7th-8th cause of death of malignant tumors. In order to further improve the effect of gemcitabine in the treatment of advanced pancreatic cancer, many drugs are combined with gemcitabine in the treatment of advanced pancreatic cancer, including cisplatin, capecitabine, and docetaxel. Although the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7068A61K31/575A61P35/00
CPCA61K31/575A61K31/7068A61K2300/00
Inventor 张焜江森郑希何燕李冬利吴盼盼徐学涛
Owner GUANGDONG UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com